Therapeutic Apheresis · Review 01
Therapeutic plasma exchange: established procedure, indication-specific evidence
Why an established medical procedure is not automatically an established treatment for every condition or health goal.
- PROCEDURE STATUS
- Established medical procedure
- INDICATION EVIDENCE
- Established only for defined indications
- REVIEW STATUS
- Clinical review required
- NEXT REVIEW
- January 2027
In short
Therapeutic plasma exchange is an established hospital procedure with recognized uses in specific diseases. That status belongs to the procedure and to defined indications, not to every new reason for offering it. Longevity, Long COVID and broad preventive use each require their own evidence assessment and should not inherit credibility from unrelated established indications.
The clinical question
When is therapeutic plasma exchange established, and what changes when it is proposed for a new indication?
What is established
The American Society for Apheresis evaluates therapeutic apheresis indication by indication. Its ninth evidence-based special issue contains 91 fact sheets and 166 graded indications across plasma exchange, immunoadsorption and other apheresis procedures. This is the appropriate level of analysis: a named procedure, for a named patient group, for a named clinical purpose.[1]
The procedure itself is well characterized. Blood is separated, selected plasma components are removed and replacement fluid is returned with the cellular components. Known risks, vascular-access requirements, replacement-fluid effects and monitoring needs are part of established clinical practice.[1][2]
What evidence categories actually mean
ASFA categories describe the role of apheresis for a particular indication. They do not certify a machine or make a general claim that plasma exchange improves health. A use can be first-line in one disease, second-line in another, uncertain in a third and unsupported in a fourth.[1]
- Procedure status and indication evidence must be displayed separately.
- A biomarker-removal mechanism does not establish patient benefit.
- A treatment protocol cannot be borrowed from a different disease without clinical justification.
- Eligibility and risk remain individual even where an indication is established.
The distinction that matters
Established procedure does not mean established longevity intervention, established Long COVID treatment or established preventive therapy.
Safety is part of the indication decision
Plasma exchange has a known and manageable risk profile when performed by experienced teams, but it is not risk-free. Reported complications include citrate-related symptoms, blood-pressure changes, allergic reactions, vascular-access complications and changes in medications or plasma proteins. Risk depends on the patient, replacement fluid and clinical setting.[2][3]
What this means for you
At AION, plasma exchange is called established only for the procedure itself, or for a specific use that a real guideline actually supports. If you are considering it for any other reason, that request is treated as its own question: its own evidence, its own limitations, and its own decision made with your physician, not something that borrows credibility from an approved use it has nothing to do with.[1]
Source register
Every material source used in this review, with the study design and the limitation that matters when interpreting it.
- [1]Connelly-Smith L, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: The Ninth Special Issue.
Journal of Clinical Apheresis · 2023 · Evidence-based specialty guideline
PMID 37017433 · DOI 10.1002/jca.22043
- WHAT IT ADDS
- Grades therapeutic apheresis separately across 166 procedure-and-indication combinations.
- LIMITATION
- A guideline category for one indication cannot be transferred to a different indication.
- [2]Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management.
American Journal of Kidney Diseases · 1994 · Clinical experience and literature review
PMID 8203364 · DOI 10.1016/S0272-6386(12)80642-0
- WHAT IT ADDS
- Characterizes common and serious complications across clinical plasma-exchange procedures.
- LIMITATION
- Older procedural data may not represent every current device, protocol or patient population.
- [3]Hodulik KL, et al. Effects of therapeutic plasma exchange on anticoagulants in patients receiving therapeutic anticoagulation: a systematic review.
Transfusion · 2019 · Systematic review
PMID 30762882 · DOI 10.1111/trf.15191
- WHAT IT ADDS
- Shows that plasma exchange can alter anticoagulant measures and requires medication-aware management.
- LIMITATION
- The available studies were small and heterogeneous.
Research changes the question.
A physician owns the answer.
This review is educational and remains marked for clinical review. It does not determine whether any therapy is appropriate for an individual patient.